Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
Direxion Daily Real Estate Bull 3X Shares ETF
DRN
VanEck Semiconductor ETF
SMH
4
ProShares Ultra Real Estate
URE
5
The Technology Select Sector SPDR® Fund
XLK
US Stock MarketDetailed Quotes
InMed Pharmaceuticals (INM)
- 0.7621
- -0.0150-1.93%
Close Apr 23 15:58 ET
- 0.7980
- +0.0180+2.31%
Pre 08:10 ET
2.53MMarket Cap-0.26P/E (TTM)
0.8100High0.7401Low39.74KVolume0.8100Open0.7771Prev Close30.97KTurnover1.84%Turnover RatioLossP/E (Static)3.31MShares7.980052wk High0.26P/B1.65MFloat Cap0.575052wk Low--Dividend TTM2.16MShs Float3210.0000Historical High--Div Yield TTM9.00%Range %0.5750Historical Low0.7792Avg Price1Lot Size
INM Stock Chart
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
INM Orderflow
Unit: --
INM Orderflow Trend
IntradayDayWeekMonth
No Data
InMed Pharmaceuticals (INM) News
InMed Pharmaceuticals Announces ATM Offering Prospectus Filing
InMed Pharmaceuticals Faces Nasdaq Minimum Bid Price Noncompliance
InMed Warned by Nasdaq Over Minimum Bid Price Non-compliance
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
InMed Reports Preclinical Data Showing Reduced Brain Inflammation in Alzheimer's Models
Express News | InMed Pharmaceuticals Inc - Plans Pre-Ind Meeting With U.S. FDA for Inm-901 in Q3 2026 - SEC Filing
InMed Pharmaceuticals (INM) Stock Forum
$InMed Pharmaceuticals (INM.US)$
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program
March 23, 2026 7:30 AM EDT | Source: InMed Pharmaceuticals
Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical Trials
Consistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimensional Human Brain Tissue Systems
Vancouver, British Colu...
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program
March 23, 2026 7:30 AM EDT | Source: InMed Pharmaceuticals
Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical Trials
Consistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimensional Human Brain Tissue Systems
Vancouver, British Colu...
4
$InMed Pharmaceuticals (INM.US)$
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
March 09, 2026 7:30 AM EDT | Source: InMed Pharmaceuticals
Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling Activities
Targeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - InMed Pharmaceutical...
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial
March 09, 2026 7:30 AM EDT | Source: InMed Pharmaceuticals
Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling Activities
Targeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027
Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - InMed Pharmaceutical...
1
$InMed Pharmaceuticals (INM.US)$ what the hell is going on here??
$InMed Pharmaceuticals (INM.US)$ Buckle up your seat belt, cos we are ready to 🚀
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)